{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:54:40Z","timestamp":1780462480013,"version":"3.54.1"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010890","name":"Central People&apos;s Government of the People&apos;s Republic of China Scholarship Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","award":["13923"],"award-info":[{"award-number":["13923"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bone.2026.117789","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:39:09Z","timestamp":1768088349000},"page":"117789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Models of myeloma bone disease: In vivo and in vitro approaches"],"prefix":"10.1016","volume":"205","author":[{"given":"Jiaxian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.J.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.bone.2026.117789_bb0005","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma\u2013related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0015","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41408-024-01120-9","article-title":"Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients","volume":"14","author":"Joseph","year":"2024","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0020","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3111\/13696998.2015.1132225","article-title":"Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma","volume":"19","author":"Nash Smyth","year":"2016","journal-title":"J. Med. Econ."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0030","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/13696998.2018.1457531","article-title":"Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database","volume":"21","author":"Bhowmik","year":"2018","journal-title":"J. Med. Econ."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0035","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3606","article-title":"Preventing and repairing myeloma bone disease by combining conventional antiresorptive treatment with a bone anabolic agent in murine models","volume":"34","author":"Paton-Hough","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0040","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1359\/jbmr.090901","article-title":"Myeloma bone disease","volume":"24","author":"Sanderson","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0045","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00774-023-01403-4","article-title":"Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents","volume":"41","author":"Teramachi","year":"2023","journal-title":"J. Bone Miner. Metab."},{"issue":"33","key":"10.1016\/j.bone.2026.117789_bb0050","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0055","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jbmr.1822","article-title":"Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery","volume":"28","author":"Jacome-Galarza","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117789_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcdb.2020.05.016","article-title":"Osteoclast formation at the bone marrow\/bone surface interface: importance of structural elements, matrix, and intercellular communication","volume":"112","author":"S\u00f8e","year":"2021","journal-title":"Semin. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0065","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0070","article-title":"The RANK-RANKL-OPG system: a multifaceted regulator of homeostasis, immunity, and cancer","volume":"59","author":"De Leon-Oliva","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0080","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/en.2004-1343","article-title":"Minireview: transcriptional regulation in development of bone","volume":"146","author":"Kobayashi","year":"2005","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41421-024-00689-6","article-title":"Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0090","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","article-title":"Osteocyte control of osteoclastogenesis","volume":"54","author":"O\u2019Brien","year":"2013","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00223-013-9790-y","article-title":"Osteocytes: master orchestrators of bone","volume":"94","author":"Schaffler","year":"2014","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0100","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/jbmr.2740","article-title":"Pannexin-1 and P2X7-receptor are required for apoptotic osteocytes in fatigued bone to trigger RANKL production in neighboring bystander osteocytes","volume":"31","author":"Cheung","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0105","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/ijms17122045","article-title":"Cell death in chondrocytes, osteoblasts, and osteocytes","volume":"17","author":"Komori","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jemt.10374","article-title":"Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities","volume":"61","author":"Delaiss\u00e9","year":"2003","journal-title":"Microsc. Res. Tech."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/boneres.2015.32","article-title":"Pit- and trench-forming osteoclasts: a distinction that matters","volume":"3","author":"Merrild","year":"2015","journal-title":"Bone Research."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0120","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3934\/mbe.2020063","article-title":"Bone remodeling platforms: understanding the need for multicellular lab-on-a-chip systems and predictive agent-based models","volume":"17","author":"Sharon","year":"2020","journal-title":"Math. Biosci. Eng."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41580-020-00279-w","article-title":"Mechanisms of bone development and repair","volume":"21","author":"Salhotra","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","article-title":"Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction","volume":"5","author":"Tatsumi","year":"2007","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0135","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41467-020-17099-3","article-title":"A FAK\/HDAC5 signaling axis controls osteocyte mechanotransduction","volume":"11","author":"Sato","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bone.2026.117789_bb0140","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0145","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3390\/ijms22126208","article-title":"Myeloma bone disease: a comprehensive review","volume":"22","author":"Mukkamalla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bone.2026.117789_bb0150","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13550-016-0197-4","article-title":"(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma","volume":"6","author":"Regelink","year":"2016","journal-title":"EJNMMI Res."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0160","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.18588","article-title":"In vivo F-fluoride-PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients","volume":"200","author":"Regelink","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.bone.2026.117789_bb0165","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"13","key":"10.1016\/j.bone.2026.117789_bb0170","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"Pt 7","key":"10.1016\/j.bone.2026.117789_bb0180","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1242\/jcs.02883","article-title":"Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro","volume":"119","author":"Spencer","year":"2006","journal-title":"J. Cell Sci."},{"issue":"24","key":"10.1016\/j.bone.2026.117789_bb0185","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1158\/0008-5472.CAN-12-2664","article-title":"p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction","volume":"72","author":"He","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0190","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2022","article-title":"PTHrP produced by myeloma plasma cells regulates their survival and pro-osteoclast activity for bone disease progression","volume":"29","author":"Cafforio","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"13","key":"10.1016\/j.bone.2026.117789_bb0195","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-\u03baB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-18-1537","article-title":"Role of the RANK\/RANKL pathway in multiple myeloma","volume":"25","author":"Raje","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bone.2026.117789_bb0205","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1\u03b1 on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0215","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.2024.286484","article-title":"A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma","volume":"110","author":"Anloague","year":"2025","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0220","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2013.385","article-title":"Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma","volume":"28","author":"Silbermann","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0225","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcb.10613","article-title":"Activin A stimulates I\u03baB-\u03b1\/NF\u03baB and rank expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors","volume":"90","author":"Sugatani","year":"2003","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0230","article-title":"Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-\u03baB, ERK and JNK signaling pathways","volume":"7","author":"Feng","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0235","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1084\/jem.182.5.1461","article-title":"Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors","volume":"182","author":"Udagawa","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bone.2026.117789_bb0240","first-page":"9","article-title":"Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma","author":"Harmer","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0245","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-\u03b1 and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatology"},{"issue":"17","key":"10.1016\/j.bone.2026.117789_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174441","article-title":"Myeloma-bone interaction: a vicious cycle via TAK1-PIM2 signaling","volume":"13","author":"Harada","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0255","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.14388","article-title":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma","volume":"180","author":"Teramachi","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0260","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bone.2026.117789_bb0265","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0270","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/jbmr.52","article-title":"TNF-\u03b1\u2019s effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression","volume":"25","author":"Ghali","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0275","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (CC motif) ligand 20","volume":"30","author":"Dalla Palma","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0280","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/leu.2009.129","article-title":"Genetic polymorphisms of EPHX1, Gsk3\u03b2, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma","volume":"23","author":"Durie","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0285","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0290","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180262","article-title":"Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice","volume":"9","author":"Liu","year":"2019","journal-title":"Open Biol."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0295","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1182\/blood.V104.11.2356.2356","article-title":"Myeloma cells suppress osteoblast differentiation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"104","author":"Oshima","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bone.2026.117789_bb0300","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","article-title":"Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment","volume":"67","author":"Giuliani","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0305","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2026.117789_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0320","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0325","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0330","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0335","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bone.2026.117789_bb0340","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1182\/blood.V124.21.5672.5672","article-title":"The effects of CCL3 on osteoblast inhibition in myeloma-induced bone disease","volume":"124","author":"Fu","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0345","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009870","article-title":"TGF-\u03b2 inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS One"},{"issue":"33","key":"10.1016\/j.bone.2026.117789_bb0355","doi-asserted-by":"crossref","first-page":"55405","DOI":"10.18632\/oncotarget.19265","article-title":"Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0360","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/leu.2012.126","article-title":"Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway","volume":"26","author":"Xu","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0365","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.bone.2026.117789_bb0370","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","article-title":"The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth","volume":"114","author":"Pennisi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0375","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","article-title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma","volume":"29","author":"Hiasa","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0380","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)62556-4","article-title":"Expression of CD56\/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation","volume":"160","author":"Ely","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0385","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00163574","article-title":"Myeloma affects both the growth and function of human osteoblast-like cells","volume":"10","author":"Evans","year":"1992","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0390","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2141.2003.04374.x","article-title":"Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease","volume":"122","author":"Silvestris","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0395","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1096\/fj.05-4329fje","article-title":"A role of TRAIL in killing osteoblasts by myeloma cells","volume":"20","author":"Tinhofer","year":"2006","journal-title":"FASEB J."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0400","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0405","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2026.117789_bb0410","first-page":"12","article-title":"Animal models of multiple myeloma bone disease","author":"Mehdi","year":"2021","journal-title":"Front. Genet."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0415","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.molmed.2020.01.016","article-title":"Development of humanized ossicles: bridging the hematopoietic gap","volume":"26","author":"Dupard","year":"2020","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0420","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol."},{"issue":"325","key":"10.1016\/j.bone.2026.117789_bb0425","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.morpho.2015.01.003","article-title":"The use of animal models in multiple myeloma","volume":"99","author":"Libouban","year":"2015","journal-title":"Morphologie"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0430","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/1097-0142(19850301)55:5<1030::AID-CNCR2820550518>3.0.CO;2-Y","article-title":"Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma","volume":"55","author":"Radl","year":"1985","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0435","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0440","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"13","key":"10.1016\/j.bone.2026.117789_bb0445","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0450","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol. J."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0455","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.bone.2026.117789_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041127","article-title":"Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma","volume":"7","author":"Buckle","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0465","doi-asserted-by":"crossref","DOI":"10.1038\/srep30998","article-title":"Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss","volume":"6","author":"Deshet-Unger","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0470","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0475","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.V93.5.1697","article-title":"Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease","volume":"93","author":"Dallas","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0480","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1158\/1535-7163.MCT-07-0121","article-title":"Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging","volume":"6","author":"Oyajobi","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0485","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bone.2026.117789_bb0490","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1158\/1078-0432.CCR-08-0285","article-title":"Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma","volume":"14","author":"Murillo","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0495","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2005-09-3870","article-title":"Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma","volume":"107","author":"Goel","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bone.2026.117789_bb0500","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3390\/cancers13174277","article-title":"An improved animal model of multiple myeloma bone disease","volume":"13","author":"Mehdi","year":"2021","journal-title":"Cancers"},{"issue":"11\u221212","key":"10.1016\/j.bone.2026.117789_bb0505","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1242\/dmm.003160","article-title":"A murine model of myeloma that allows genetic manipulation of the host microenvironment","volume":"2","author":"Fowler","year":"2009","journal-title":"Dis. Model. Mech."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0510","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1210\/en.2017-03083","article-title":"Thymic PTH increases after thyroparathyroidectomy in C57BL\/KaLwRij mice","volume":"159","author":"Zangari","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2026.117789_bb0515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbo.2018.02.005","article-title":"Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo","volume":"12","author":"Zangari","year":"2018","journal-title":"J. Bone Oncol."},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051892","article-title":"A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease","volume":"7","author":"Hofgaard","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0525","first-page":"227","article-title":"Mouse plasmacytoma: an experimental model of human multiple myeloma","volume":"86","author":"Gado","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2026.117789_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.214047","article-title":"Bone mechanical properties were altered in a mouse model of multiple myeloma bone disease","volume":"166","author":"Rummler","year":"2025","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.bone.2026.117789_bb0535","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.actbio.2020.10.041","article-title":"Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease","volume":"119","author":"Rummler","year":"2021","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0540","article-title":"An early myeloma bone disease model in skeletally mature mice as a platform for biomaterial characterization of the extracellular matrix","volume":"2020","author":"Ziouti","year":"2020","journal-title":"J. Oncol."},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0545","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI200420369","article-title":"Novel targeted deregulation of c-Myc cooperates with Bcl-XL to cause plasma cell neoplasms in mice","volume":"113","author":"Cheung","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0550","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0555","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0560","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2020007156","article-title":"Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice","volume":"137","author":"Wen","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0565","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0570","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ni907","article-title":"Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1","volume":"4","author":"Iwakoshi","year":"2003","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0575","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219439120","article-title":"Mouse models of human multiple myeloma subgroups","volume":"120","author":"Winkler","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0580","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","article-title":"Development of an in vivo model of human multiple myeloma bone disease","volume":"87","author":"Alsina","year":"1996","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0585","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0590","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exphem.2004.01.006","article-title":"Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts","volume":"32","author":"Doran","year":"2004","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0595","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","article-title":"Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice","volume":"14","author":"Hjorth-Hansen","year":"1999","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease","volume":"10","author":"Lawson","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0605","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood.V90.6.2437","article-title":"New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor","volume":"90","author":"Tsunenari","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0610","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/sj.leu.2404814","article-title":"A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer","volume":"21","author":"Rabin","year":"2007","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.bone.2026.117789_bb0615","first-page":"6689","article-title":"Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: biologic and clinical implications","volume":"63","author":"Mitsiades","year":"2003","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0620","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","article-title":"The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects","volume":"27","author":"Hurchla","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0625","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/jbmr.3859","article-title":"TGF\u03b2 inhibition stimulates collagen maturation to enhance bone repair and fracture resistance in a murine myeloma model","volume":"34","author":"Green","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117789_bb0630","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bone.2015.10.004","article-title":"Osteolytica: an automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods","volume":"83","author":"Evans","year":"2016","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0635","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3324\/haematol.12349","article-title":"A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect","volume":"93","author":"Rozemuller","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0640","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00223-009-9284-0","article-title":"Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model","volume":"85","author":"Postnov","year":"2009","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0645","first-page":"3198","article-title":"Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice Copurify with CD34+ hematopoietic progenitors1","volume":"8","author":"Pilarski","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0650","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177300","article-title":"Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice","volume":"9","author":"Hasanali","year":"2024","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0655","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2005-01-0373","article-title":"A clinically relevant SCID-hu in vivo model of human multiple myeloma","volume":"106","author":"Tassone","year":"2005","journal-title":"Blood"},{"issue":"4873","key":"10.1016\/j.bone.2026.117789_bb0660","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.2971269","article-title":"The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function","volume":"241","author":"McCune","year":"1988","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0665","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V90.2.754","article-title":"The development of a model for the homing of multiple myeloma cells to human bone marrow","volume":"90","author":"Urashima","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bone.2026.117789_bb0670","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0675","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0680","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0685","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0690","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0695","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0700","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0705","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/leu.2010.300","article-title":"A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells","volume":"25","author":"Calimeri","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0710","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2012-03-414920","article-title":"Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma","volume":"120","author":"Groen","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bone.2026.117789_bb0715","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/biom15121747","article-title":"Humanized bone model identifies BMP6 as a multifunctional regulator in myeloma bone disease","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.bone.2026.117789_bb0720","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1355044","article-title":"The (misleading) role of animal models in drug development","volume":"4","author":"Hartung","year":"2024","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.bone.2026.117789_bb0725","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fbioe.2018.00134","article-title":"In vitro models of bone remodelling and associated disorders","volume":"6","author":"Owen","year":"2018","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0730","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bone.2026.117789_bb0735","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2008-02-142430","article-title":"A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma","volume":"112","author":"Kirshner","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bone.2026.117789_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071613","article-title":"Ex-vivo dynamic 3-D culture of human tissues in the RCCS\u2122 bioreactor allows the study of multiple myeloma biology and response to therapy","volume":"8","author":"Ferrarini","year":"2013","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.bone.2026.117789_bb0745","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bone.2026.117789_bb0750","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2018.01.023","article-title":"Development of a 3D bone marrow adipose tissue model","volume":"118","author":"Fairfield","year":"2019","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0755","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/ten.tec.2017.0467","article-title":"Endosteal and perivascular subniches in a 3D bone marrow model for multiple myeloma","volume":"24","author":"Braham","year":"2018","journal-title":"Tissue Eng. Part C Methods"},{"issue":"8","key":"10.1016\/j.bone.2026.117789_bb0760","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/ten.tec.2013.0490","article-title":"Patient-specific 3D microfluidic tissue model for multiple myeloma","volume":"20","author":"Zhang","year":"2014","journal-title":"Tissue Eng. Part C Methods"},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0765","article-title":"Ex vivo maintenance of primary human multiple myeloma cells through the optimization of the osteoblastic niche","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0770","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/jbmr.4404","article-title":"A functional three-dimensional microphysiological human model of myeloma bone disease","volume":"36","author":"Visconti","year":"2021","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2026.117789_bb0775","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2020.02.011","article-title":"Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery","volume":"26","author":"Sharma","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0780","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/2159-8290.CD-22-0199","article-title":"Human bone marrow organoids for disease modeling, discovery, and validation of therapeutic targets in hematologic malignancies","volume":"13","author":"Khan","year":"2023","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bone.2026.117789_bb0785","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41592-024-02172-2","article-title":"Generation of complex bone marrow organoids from human induced pluripotent stem cells","volume":"21","author":"Frenz-Wiessner","year":"2024","journal-title":"Nat. Methods"},{"key":"10.1016\/j.bone.2026.117789_bb0790","article-title":"Human bone marrow organoids: emerging progress but persisting challenges","author":"Bourgine","year":"2025","journal-title":"Trends Biotechnol."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0795","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10252","article-title":"Differential pain-related behaviors and bone disease in immunocompetent mouse models of myeloma","volume":"4","author":"Diaz-delCastillo","year":"2020","journal-title":"JBMR Plus."},{"issue":"2","key":"10.1016\/j.bone.2026.117789_bb0800","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL1","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"11","key":"10.1016\/j.bone.2026.117789_bb0805","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.4202","article-title":"Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice","volume":"22","author":"Das","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0810","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13734","article-title":"Drug metabolism in animal models and humans: translational aspects and chances for individual therapy","volume":"233","author":"Indorf","year":"2021","journal-title":"Acta Physiol."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0815","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0820","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1242\/dev.102210","article-title":"Skeletal stem cells","volume":"142","author":"Bianco","year":"2015","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.bone.2026.117789_bb0825","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bone.2026.117789_bb0830","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.stemcr.2015.04.010","article-title":"Transcriptome-wide analysis reveals hallmarks of human intestine development and maturation in vitro and in vivo","volume":"4","author":"Finkbeiner","year":"2015","journal-title":"Stem Cell Rep."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0835","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13287-019-1209-x","article-title":"Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature","volume":"10","author":"Spitzhorn","year":"2019","journal-title":"Stem Cell Res. Ther."},{"issue":"10","key":"10.1016\/j.bone.2026.117789_bb0840","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1038\/s41596-019-0189-8","article-title":"Engineering of human cardiac muscle electromechanically matured to an adult-like phenotype","volume":"14","author":"Ronaldson-Bouchard","year":"2019","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0845","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.stem.2019.11.011","article-title":"Circadian entrainment triggers maturation of human in vitro islets","volume":"26","author":"Alvarez-Dominguez","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.bone.2026.117789_bb0850","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-025-56569-4","article-title":"iPSCs and iPSC-derived cells as a model of human genetic and epigenetic variation","volume":"16","author":"Quaid","year":"2025","journal-title":"Nat. Commun."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:51:25Z","timestamp":1774061485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":170,"alternative-id":["S8756328226000153"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117789","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Models of myeloma bone disease: In vivo and in vitro approaches","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117789"}}